Chugai’s Enspryng (Satralizumab) Approved by European Commission as First At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche has been granted Marketing Authorization from the European Commission for the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Enspryng® (satralizumab), created by Chugai, as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). Enspryng is the first treatment approved in the EU for adolescents from 12 years of age with NMOSD.
“We are very pleased that Enspryng is now approved in the EU as the first subcutaneous treatment for people with AQP4-IgG seropositive NMOSD, with the option to be treated at home,” said Chugai’s President and CEO, Dr. Osamu Okuda. “Enspryng is the first approved therapeutic antibody for which our proprietary recycling antibody technology was applied. We are confident that Enspryng will meaningfully contribute to improving the treatment of people with NMOSD, by fitting into their day-to-day lives.”
The efficacy and safety of Enspryng has been evaluated in large clinical trials representative of the real-world population of people with NMOSD, including those who have only experienced a single NMOSD attack and adolescents. The approval by the European Commission is based on the results from two global phase III clinical studies in people with NMOSD: SAkuraSky Study (NCT02028884) and SAkuraStar Study (NCT02073279). SAkuraSky evaluated Enspryng in combination with baseline immunosuppressive treatment, and SAkuraStar assessed monotherapy.
Enspryng is designed to prevent NMOSD relapses by inhibiting IL-6 signal signaling, which is a key driver in NMOSD. Enspryng is currently approved in 54 countries including Japan, the United States and EU countries.
The impact on the consolidated financials for the fiscal year ending December 2021 of Chugai is expected to be negligible.
*Self-administration is not covered in Japan at this time
**Subcutaneous administration at 2-week intervals up to the fourth week of treatment and at 4-week intervals thereafter
New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD) (September 10, 2020)
Results from Phase III SAkuraSky Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in The New England Journal of Medicine Online (November 29, 2019)
Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in The Lancet Neurology (April 24, 2020)
About neuromyelitis optica spectrum disorder (NMOSD)1
NMOSD is an autoimmune disease of the central nervous system characterized by inflammatory lesions in the optic nerves and spinal cord, and causes a continual and significant decrease in quality of life due to permanent neurological disability. Patients with NMOSD frequently experience a relapsing disease course with repeated attacks leading to accumulating neurological damage and disability. Symptoms may include visual impairment, motor disability, pain leading to decreased quality of life. In some cases, attacks of NMOSD result in death. Aquaporin-4 antibodies (AQP4-IgG), pathogenic antibodies, are detected in around 70-80% of NMOSD people. AQP4-IgG is known to target and damage a specific central nervous cell type called astrocytes, resulting in inflammatory demyelinating lesions of the optic nerve(s), spinal cord and brain 2-5. The inflammatory cytokine IL-6 is now emerging as an important factor in NMOSD pathogenesis 6-10.
Trademarks used or mentioned in this release are protected by law.
1. Neuromyelitis optica spectrum disorder (NMOSD) Online. https://nmosd-online.jp/ Accessed June 2021. (Japanese only)
2. Jarius S, Ruprecht K, Wildemann B et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
3. Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12.
4. Marignier R, Bernard-Valnet R, Giraudon P et al. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology 2013;80:2194-200.
5. Takahashi T, Fujihara K, Nakashima I et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-43.
6. Chihara N, Aranami T, Sato W et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011;108:3701-6.
7. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010;40:1830-5.
8. Lin J, Li X, Xia J. Th17 cells in neuromyelitis optica spectrum disorder: a review. Int J Neurosci2016;126:1051-60.
9. Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e311.
10. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013;19:1584-96.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma U.K. Ltd.
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taulia Appoints Todd Musselman as Chief Wellbeing Officer25.10.2021 10:00:00 CEST | Press release
Taulia, the leading fintech provider of working capital solutions, has today announced the appointment of Todd Musselman as Chief Wellbeing Officer, reflecting the business’ commitment to prioritizing employee wellbeing, happiness and development. Musselman brings with him extensive leadership coaching experience, having run his own business that offers motivational speaking, leadership training and executive coaching. Prior to this, Todd worked for his family’s company for over 25 years where he played an integral role in product development, marketing and sales strategies and guiding those in management positions. Under Todd’s leadership, Taulia will strengthen its wellness culture, empowering its 300+ employees around the world to put their wellbeing first, helping them maximize their professional and personal performance and development. Cedric Bru, CEO at Taulia comments: “The wellness of our employees is of paramount importance to our business. We want to continue investing to en
Cat Rock Capital Sends Letter to Just Eat Takeaway.com (“JET”) Board Urging Sale or Spin-Off of Grubhub by End of 202125.10.2021 10:00:00 CEST | Press release
Cat Rock Capital Management LP (together with its affiliates, “Cat Rock Capital”), a long-term oriented investment firm and holder of approximately 13.8 million shares in the capital of Just Eat Takeaway.com NV (“Just Eat Takeaway.com”, “JET”, or “the Company”) (LSE: JET, AMS: TKWY, NASDAQ: GRUB), representing circa 6.5% of Just Eat Takeaway.com’s outstanding shares, today sent a letter to the JET Management Board. Cat Rock urges the announcement of a sale or spin-off of Grubhub by 31 December 2021 to refocus JET’s business and address the deep and damaging undervaluation of the Company’s equity. This letter is included below and is also available at JustEatMustDeliver.com. Alex Captain, Founder and Managing Partner, Cat Rock Capital Management LP, commented: “We were pleased to see Just Eat Takeaway.com present a clear, data-driven vision for its business at the recent Capital Markets Day. Moreover, we were encouraged to hear that JET management views consolidation in the US market as
Intelligent Fingerprinting’s Simple Saliva-based COVID-19 Test Now CE Marked and Available for Sale25.10.2021 09:16:00 CEST | Press release
Intelligent Fingerprinting has announced that its saliva-based COVID-19 test now carries CE marking and is available for sale. The new VSS-GP COVID-19 Saliva Test uses a simple swab to collect saliva from just inside the cheek, providing a much easier alternative to current throat and nose tests that can cause gagging, sneezing or distress during sample collection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005324/en/ The new VSS-GP COVID-19 Saliva Test from Intelligent Fingerprinting uses a simple swab to collect saliva from just inside the cheek, providing a much easier alternative to current throat and nose tests that can cause gagging, sneezing or distress during sample collection. (Photo: Business Wire) Easier, more comfortable COVID-19 testing Intelligent Fingerprinting’s reliable and easy-to-use saliva-based lateral flow test supports frequent COVID-19 testing for applications including schools, workplaces,
iBASIS Wins Best Global Wholesale Carrier – Voice at the Global Carrier Awards 202125.10.2021 08:00:00 CEST | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, won Best Wholesale Global Carrier – Voice 2021 at the 17th edition of the Global Carrier Awards (GCAs) held during Capacity Europe in London, U.K. Commending the greatest accomplishments in telecom, tech, and ICT space, the win recognizes iBASIS’ transformation under the leadership of Alexandre Pébereau, its Chief Executive Officer. In 2019, Pébereau also received the GCA for Best Strategic Acquisition of SFR ICS from the Altice Group and iBASIS from Royal KPN. The company received four additional Global Carrier Awards, including Best Strategic Acquisition of NOS International Carrier Services (NOS ICS) in 2020. “It is remarkable that iBASIS is being recognized as it celebrates the 25th anniversary of its launch of VoIP. Then, live calls on the Internet seemed impossible. Today, the transformation of Tier 1 voice services depend on the very same platform,” comments Pébereau. “This win
EIG Signs Agreement to Acquire 10% Interest in APLNG for US$1.592 Billion24.10.2021 23:30:00 CEST | Press release
EIG, a leading institutional investor to the global energy and infrastructure sectors, today announced that it has entered into a definitive agreement under which it will acquire a 10% interest in Australia Pacific LNG Pty Limited (“APLNG” or the “Project”) from Origin Energy Limited (“Origin”) for an equity purchase price of $1.592 billion. This innovative agreement represents the first ever acquisition of an interest in an operational integrated LNG project by a private equity sponsor. Asset Highlights and Strategic Rationale A tier-one, integrated LNG project with an established liquefaction facility, APLNG is the largest LNG project by liquefaction capacity on Australia’s eastern seaboard and a major supplier of LNG to Asia and gas to Australia’s domestic market. The Project, which is located in Gladstone, Queensland, has a track record of consistently achieving its nameplate capacity of 9.0 Mtpa and holds a leading acreage position spanning the prolific Surat and Bowen basins, pro
SES-17 Successfully Launched on Ariane 524.10.2021 06:08:00 CEST | Press release
SES announced today that the SES-17 satellite was successfully launched into space onboard an Ariane 5 launcher operated by Arianespace from the Europe’s Spaceport in Kourou, French Guiana at 11:10 pm local time (02:10 am UTC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211023005019/en/ SES-17 Successfully Launched on Ariane 5 (Photo: Business Wire) The multi-mission Ka-band satellite will provide comprehensive coverage across the Americas, the Caribbean and the Atlantic Ocean. From its orbital slot of 67.1 degrees West orbital slot, the very high throughput geostationary (GEO) satellite incorporating cutting-edge technologies is set to deliver the best connectivity experience for SES customers operating in the aeronautical, maritime, enterprise, and government markets. Built by Thales Alenia Space, SES-17 marks an important milestone in satellite technology as the first Ka-band geostationary satellite to embark a fully
Peru Holds a Ribbon Cutting Ceremony at Its Pavilion at Dubai Expo and Wins 4 World Travel Awards22.10.2021 19:15:00 CEST | Press release
The Dubai World Expo took place in an electrifying musical atmosphere where thousands of attendees were captivated by the variety of artistic, musical and cultural expressions that characterize the different regions of Peru. All this was part of the inauguration of the Peru Pavilion at the most important cultural event in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211022005454/en/ Peru inaugurated its Pavilion at Expo 2020 Dubai and received four awards from the “Tourism Oscars.” (Photo: Business Wire) The Peru Pavilion was inaugurated by the Commissioner General for Peru at the Expo, Amora Carbajal, and Najeeb Mohammed Al-Ali, Executive Director of Expo 2020 Dubai, in front of official representatives from different country pavilions. “The purpose of the pavilion is to offer a complete learning experience about ancient Peruvian wisdom throughout the visit, communicating the importance of the heritage, biodive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom